;

Discover Grünenthal

8/10/2021

Aachen, Germany, & Morristown, N.J., 10 August 2021 – Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001. The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.

7/14/2021

Aachen, Germany, 14 July 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy, announces that the company has successfully extended its existing bond financing by €300 million to a total sum of €950 million.

7/7/2021

Aachen, Germany, 7 July 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy announced that the company is extending its existing bond financing by €300 million to a total sum of €950 million.

7/6/2021

Aachen, Germany, 06 July 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy, announced today that it has launched an offering (the “Offering”) of €300,000,000 aggregate principal amount of additional senior secured notes.

5/6/2021

Aachen, Germany, 06 May 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy, announces that it has successfully closed its first bond transaction.

4/23/2021

Aachen, Germany, 23 April 2021 – Grünenthal GmbH (the “Company”) today announced the pricing of its first bond with an aggregate principal amount of €650 million. Due to strong investor demand, the original offer size was increased by €150 million.

Florian Dieckmann Head Global Communication

Florian Dieckmann

Head Global Communication


Grünenthal GmbH

52099 Aachen


Phone +49 241 569-2555

E-Mail media@grunenthal.com